Clay Matthews of the Green Bay Packers Featured in New CureDuchenne PSA to Help the Fight to Find a Cure for Duchenne Muscular Dystrophy
Newport Beach, Calif.
NEWPORT BEACH, Calif., December 18, 2014 – CureDuchenne announced today that Clay Matthews of the Green Bay Packers is featured in a new Public Service Announcement to help raise awareness about Duchenne muscular dystrophy. The PSA is part of CureDuchenne’s ongoing efforts to raise awareness and fund research to find a cure for Duchenne, a progressive muscle-wasting disease that impacts 1 in every 3,500 boys. Boys are usually diagnosed by the age of 5, in a wheelchair by 12 and most don’t survive their mid-20s. Currently, there is no cure for Duchenne.
“For someone who puts in a lot of hard work to build up my muscles and on the contrary to have boys and young men with Duchenne have the exact opposite taken away from them is disheartening,” said Matthews. “That is why I’m trying to spread awareness to get the funding we need to be that much closer to having a cure. Please donate and help cure Duchenne.”
“We are delighted that Clay Matthews continues to be a big supporter of our efforts to fund research to find a cure for Duchenne,” said Debra Miller, Founder and CEO of CureDuchenne. “Clay has a big heart and we appreciate his compassion to help those who live with Duchenne. We will continue to fund research to help accelerate access to drugs until there is a treatment for all boys with Duchenne.”
For more information on CureDuchenne go to www.cureduchenne.org or call 949-872-2552.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been as successful in being a catalyst for human clinical trials.